Artelo Uncovers Linoleic Acid Modulation Across Multiple Models with ART26.12
ARTL•Artelo Biosciences presented multi-omics analyses at ICRS 2026 showing ART26.12 consistently modulated pro-inflammatory lipid linoleic acid across multiple disease models. This phase 1 FABP5 inhibitor demonstrated common mechanistic links in cancer, pain, dermatologic and neurological systems, reinforcing its broad therapeutic potential.
1. Multi-Omics Analysis at ICRS 2026
Artelo Biosciences researchers presented integrative multi-omics data at the International Cannabinoid Research Society 2026 Annual Symposium, evaluating datasets across diverse disease models, tissues and experimental systems to uncover common biological pathways influenced by ART26.12.
2. Linoleic Acid Signaling Link
The analysis revealed consistent modulation of the pro-inflammatory lipid linoleic acid and related signaling pathways across cancer, pain, dermatologic and neurological models, suggesting a unified mechanism underlying the broad therapeutic activity of FABP5 inhibition.
3. ART26.12 Phase 1 Development
ART26.12, the lead selective FABP5 inhibitor now in Phase 1 testing for chemotherapy-induced peripheral neuropathy, has demonstrated a favorable safety profile, predictable linear pharmacokinetics and dosing flexibility in both fed and fasted states.
4. Strategic Therapeutic Potential
These findings strengthen understanding of FABP5 biology, validate cross-indication mechanistic links and enhance the appeal of Artelo’s lipid-signaling modulation strategy for prospective pharmaceutical partners exploring treatments for unmet medical needs.
